What Is Cagrilintide? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Cagrilintide is investigational and is not FDA-approved as a standalone medication. Products sold online as cagrilintide, “research use only” cagrilintide, or compounded cagrilintide may carry safety, quality, and legal risks.

Quick answer

Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk for weight management and metabolic disease. Amylin is a hormone co-secreted with insulin by pancreatic beta cells and helps regulate appetite, satiety, and food intake. Cagrilintide has shown clinically meaningful weight-loss effects in human trials, especially when combined with semaglutide as CagriSema. However, cagrilintide is not FDA-approved as a standalone medication, and CagriSema remains investigational until approved by regulators. Online cagrilintide products should be treated as unapproved and potentially unsafe.

Key facts about Cagrilintide

What is cagrilintide?

Cagrilintide is a long-acting analog of amylin, a hormone involved in appetite and satiety signaling. Amylin is naturally co-secreted with insulin from pancreatic beta cells after meals. It helps regulate food intake, gastric emptying, and satiety.

A PubMed-indexed review describes cagrilintide as a long-acting amylin analog being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in people with overweight and obesity.

Cagrilintide is also part of CagriSema, a fixed-dose combination of:

Novo Nordisk has described CagriSema as a once-weekly fixed-dose combination of a long-acting amylin analog and a GLP-1 receptor agonist. A Novo Nordisk filing announcement stated that CagriSema had been filed for FDA approval for weight management, but also stated that CagriSema was not approved in the US or EU at that time.

The key distinction:

Cagrilintide is a real clinical-stage metabolic drug candidate, but it is not an FDA-approved consumer peptide or standalone prescription medication.

How does cagrilintide work?

Cagrilintide works by mimicking amylin-related signaling.

Amylin acts in appetite-regulating brain regions and helps promote satiety. Cagrilintide is designed to be longer-acting than native amylin so that it can be dosed weekly in clinical development.

In plain English:

Cagrilintide is being studied because it may reduce appetite and food intake through amylin pathways, while semaglutide works through GLP-1 pathways. The combination may produce stronger weight-loss effects than either pathway alone.

This is why CagriSema is important. It combines two metabolic mechanisms:

But mechanism is not approval. Cagrilintide can have promising trial data and still remain investigational until regulators approve it.

What is cagrilintide used for?

Cagrilintide is being studied for metabolic conditions, but it does not yet have an FDA-approved standalone use.

What does the research show?

Human evidence for cagrilintide alone

A key phase 2 trial evaluated once-weekly cagrilintide in people with overweight and obesity.

The PubMed summary of the phase 2 cagrilintide weight-management trial states that treatment with cagrilintide in people with overweight and obesity led to significant body-weight reductions and was well tolerated.

The practical interpretation:

Cagrilintide has human clinical evidence for weight loss as an amylin analog, but that does not make it an FDA-approved standalone drug.

Human evidence for CagriSema

CagriSema combines cagrilintide with semaglutide.

A PubMed-indexed phase 2 trial in type 2 diabetes reported that co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg produced significantly greater weight loss than semaglutide and cagrilintide comparators and was well tolerated.

A PubMed-indexed 2025 trial of cagrilintide-semaglutide in adults with overweight or obesity reported that once-weekly cagrilintide-semaglutide resulted in significantly lower body weight than placebo.

Novo Nordisk also reported that CagriSema 2.4 mg/2.4 mg produced 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity in REDEFINE 1 under the estimand assuming all patients adhered to treatment. The Novo Nordisk/PRNewswire REDEFINE 1 publication announcement also reported 20.4% weight loss regardless of adherence versus 3.0% for placebo.

The practical interpretation:

CagriSema has strong late-stage clinical evidence for weight loss, but clinical-trial success and FDA filing are not the same as approval.

Human evidence for type 2 diabetes

Novo Nordisk announced phase 3 REIMAGINE 2 results in type 2 diabetes. The Novo Nordisk REIMAGINE 2 announcement stated that CagriSema demonstrated superior HbA1c reduction and weight loss at week 68 versus semaglutide across all tested doses.

The practical interpretation:

CagriSema may become important in type 2 diabetes, but approval status and final labeling depend on regulatory review.

Evidence summary

Is cagrilintide FDA-approved?

No. Cagrilintide is not FDA-approved as a standalone medication.

CagriSema, the combination of cagrilintide and semaglutide, has been filed for FDA approval according to Novo Nordisk-related announcements, but filing for approval is not the same as being approved.

A Drugs.com CagriSema FDA approval status page listed CagriSema as not FDA-approved as of its February 2026 update.

The key distinction:

Cagrilintide has real clinical evidence, but there is no FDA-approved standalone cagrilintide product for consumers. CagriSema should also be treated as investigational unless and until FDA approval is granted.

Is cagrilintide legal?

Cagrilintide is not legally available as a normal FDA-approved prescription medication.

It may be available to eligible participants through legitimate clinical trials. It should not be treated as legal, safe, or approved just because an online seller offers it as a peptide, research chemical, or compounded product.

The blunt version:

If a website is selling cagrilintide directly to consumers, it is not selling an FDA-approved medication.

Is cagrilintide banned in sports?

I did not find cagrilintide specifically named on the WADA prohibited list in the sources reviewed here.

However, the WADA Prohibited List includes broad categories, including non-approved substances under S0. Because cagrilintide is not approved as a standalone human therapeutic drug, athletes should not assume it is permitted.

The practical advice:

Athletes should check Global DRO, WADA, or USADA before using cagrilintide, CagriSema, or any investigational metabolic drug. Online research-use products are especially high-risk.

Safety and side effects

Cagrilintide has promising clinical-trial data, but it is still being evaluated.

Common adverse effects in trials are generally gastrointestinal, similar to other appetite and metabolic medications. These may include:

• Nausea
• Vomiting
• Constipation
• Diarrhea
• Decreased appetite
• Abdominal discomfort
• Injection-site reactions

Important safety uncertainties include:

• Long-term safety
• Final approved dosing, if approved
• Final contraindications and warnings, if approved
• Risks in broader real-world populations
• Safety when combined with semaglutide
• Product-quality risks from online sellers
• Dosing errors from self-mixed or unapproved products
• Counterfeit, contaminated, or mislabeled products

A serious evaluation of cagrilintide should separate clinical-trial cagrilintide and CagriSema from gray-market cagrilintide products.

Cagrilintide vs similar drugs and peptides

The key distinction:

Cagrilintide is an amylin analog. It is not a GLP-1 receptor agonist, a GIP/GLP-1 drug, a repair peptide, or a growth hormone secretagogue.

Why is cagrilintide sold as “research use only”?

Some online sellers use “research use only” language to sell cagrilintide before approval. That is a red flag.

A serious reader should understand this distinction:

How to evaluate cagrilintide claims online

Bottom line

Cagrilintide is a long-acting amylin analog being developed for weight management and metabolic disease. It has meaningful human clinical evidence for weight loss, especially as part of CagriSema with semaglutide. But cagrilintide is not FDA-approved as a standalone medication, and CagriSema remains investigational unless and until regulators approve it.

The most defensible conclusion is:

Cagrilintide is one of the most important investigational amylin-based obesity drugs, but it should be treated as a clinical-stage medication, not a consumer peptide. Readers should avoid online cagrilintide, research-use cagrilintide, and gray-market products that are not part of legitimate clinical care or clinical trials.

FAQ

What is cagrilintide?

Cagrilintide is a long-acting amylin analog being developed by Novo Nordisk for weight management and metabolic disease.

What does cagrilintide do?

Cagrilintide mimics amylin-related satiety signaling. It may reduce appetite and food intake, which can contribute to weight loss.

Is cagrilintide FDA-approved?

No. Cagrilintide is not FDA-approved as a standalone medication.

Is CagriSema FDA-approved?

CagriSema has been filed for FDA approval according to Novo Nordisk-related announcements, but filing does not equal approval. It should be treated as investigational unless and until FDA approval is granted.

What is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg being developed by Novo Nordisk for weight management and type 2 diabetes.

Is cagrilintide the same as semaglutide?

No. Cagrilintide is an amylin analog. Semaglutide is a GLP-1 receptor agonist.

Is cagrilintide the same as tirzepatide?

No. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Cagrilintide is an amylin analog.

Does cagrilintide work for weight loss?

Human clinical trials suggest cagrilintide can produce significant weight loss, and the CagriSema combination has shown substantial weight-loss effects. However, cagrilintide is not FDA-approved as a standalone medication.

Is cagrilintide safe?

Cagrilintide has been studied in human clinical trials, but it remains investigational. Common side effects are generally gastrointestinal, and long-term safety and final labeling are still subject to regulatory review.

Is cagrilintide banned in sports?

I did not find cagrilintide specifically named on the WADA prohibited list in the sources reviewed here. However, because it is investigational and not FDA-approved as a standalone drug, athletes should verify status through WADA, USADA, or Global DRO before use.

Why do sellers call cagrilintide “research use only”?

Sellers often use “research use only” language because cagrilintide is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically equivalent to trial-grade cagrilintide.

What is the biggest risk with cagrilintide?

The biggest risk is using an unapproved drug outside clinical trials or buying online cagrilintide with unknown quality, concentration, sterility, identity, and safety.

Sources

1. PubMed: Once-weekly cagrilintide for weight management in people with overweight and obesity
2. Lancet: Once-weekly cagrilintide for weight management in people with overweight and obesity
3. PubMed: A Long-Acting Amylin Analog for the Treatment of Obesity
4. PubMed: Efficacy and safety of co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes
5. PubMed: Cagrilintide-Semaglutide in Adults with Overweight or Obesity
6. Novo Nordisk: REIMAGINE 2 Phase 3 Results
7. Novo Nordisk / PRNewswire: CagriSema FDA Filing
8. Novo Nordisk / PRNewswire: REDEFINE 1 CagriSema Results
9. ClinicalTrials.gov: CagriSema in Excess Body Weight and Type 2 Diabetes
10. Drugs.com: CagriSema FDA Approval Status
11. WADA: Prohibited List